Shuttle Pharma Reports $0 Revenue, $(2.15M) Q1 Loss Amid Strategic Pivot to AI and Dogecoin
SHPH sits 32% above its 52-week low of $0.5.
Summary
Shuttle Pharmaceuticals Holdings, Inc. reported first-quarter 2026 results with $0 revenue and a net loss of $(2.15M), or $(0.43) per share. While still reflecting a pre-revenue state, these figures represent an improvement in net loss and EPS compared to the prior year. The report also detailed the acquisition of Molecule.ai for an AI-driven molecular discovery platform and the winding down of Ropidoxuridine clinical trials, signaling a strategic shift away from traditional pharmaceuticals. This follows the company's recent merger with United Dogecoin Inc. and pivot to Dogecoin mining, as announced on May 7th. For a micro-cap company with a prior going concern warning, these results and strategic updates are crucial for investors assessing the company's ongoing transformation and future viability. Investors will be watching for further details on the integration of Molecule.ai, the progress of the Dogecoin mining operations, and future financial reports to see the impact of these strategic shifts on revenue generation and profitability.
At the time of this announcement, SHPH was trading at $0.66 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.50 to $6.19. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.